ライフサイエンスコーパス: mycotic

1 We describe the first case report of a mycotic abdominal aortic aneurysm secondary to Capnocyto

2 and endovascular aneurysm repair (EVAR) for mycotic abdominal aortic aneurysms (MAAAs).

3 in addition to a limited number of systemic mycotic agents.

4 atic, dissecting, serpentine, posttraumatic, mycotic and giant aneurysms with or without intra-aneury

5 er (n = 6), intramural hematoma (n = 2), and mycotic aneurysm (n = 2).

6 eomyelitis with an adjacent abdominal aortic mycotic aneurysm caused by a highly penicillin-resistant

7 We report a case of extra-aortic mycotic aneurysm following a sore throat without demonst

8 due to the rupture of a partially thrombosed mycotic aneurysm into the biliary tree.

9 case of a 51-year-old woman who developed a mycotic aneurysm of the aorta secondary to construction

10 The illness was complicated by a ruptured mycotic aneurysm of the right brachial artery, with comp

11 ascular lesions (a right PICA aneurysm and a mycotic aneurysm) in 2 separate patients (yield of 4.3%)

12 ections, including 2 patients with an aortic mycotic aneurysm, caused significant morbidity.

13 c agents of both vertebral osteomyelitis and mycotic aneurysm.

14 agic dural arteriovenous fistulas and distal/mycotic aneurysms are often managed with embolization if

15 e of in situ prosthetic grafts for repair of mycotic aneurysms is appropriate in certain situations a

16 of a 56-year-old man who developed multiple mycotic aneurysms of the right hepatic artery and massiv

17 Mycotic aneurysms, although uncommon, carry the addition

18 sses, connective tissue disorders, fistulas, mycotic aneurysms, and procedural sequelae.

19 Mycotic aneurysms, especially outside the aorta, are unc

20 Mycotic aortic aneurysm (MAA) is a rare and life-threate

21 t were acute with rupture, acute dissection, mycotic aortitis, and trauma.

22 cal syndromes in this dog with a fulminating mycotic disease mimicked those observed in dogs infected

23 are among the most common causes of invasive mycotic disease, with Candida albicans reigning as the l

24 are only a few species that account for most mycotic diseases, implies a remarkable natural resistanc

25 is, tuberculosis, bacteremia, and endogenous mycotic endophthalmitis.

26 Aside from an increased risk of mycotic genital infections, empagliflozin-treated patien

27 ew species Chrysosporium ophiodiicola from a mycotic granuloma of a black rat snake (Elaphe obsoleta

28 ended hypothermia), developed a disseminated mycotic infection in the lungs and kidneys.

29 urysms are rare cases resulting from trauma, mycotic infection, head and neck carcinomas or complicat

30 from 19 humans with culture-proven cases of mycotic infection.

31 s heretofore have not been reported to cause mycotic infections (i.e., F. armeniacum, F. brachygibbos

32 oup, we recorded a greater number of genital mycotic infections (women: 26 [11%] and 34 [14%] vs five

33 te to the skewing of immune responses during mycotic infections and have implications for the design

34 The therapeutic landscape for mycotic infections is shifting.

35 Genital mycotic infections were increased with SGLT-2 inhibitors

36 Genital mycotic infections were more common for SGLT2i initiator

37 host response of extravasated neutrophils to mycotic infections within tissues necessitates contact w

38 ors include euglycemic ketoacidosis, genital mycotic infections, and volume depletion.

39 Diarrhea, genital mycotic infections, volume depletion, and diabetic ketoa

40 al therapeutic options for treating invasive mycotic infections.

41 infection caused by hematogenous seeding of mycotic organisms to the eye.

42 Chest CT imaging showed a mycotic right atrial pseudoaneurysm with pericarditis an

43 The randomized controlled Mycotic Ulcer Treatment Trial (MUTT) I showed a benefit

44 riconazole, 1%, and after the results of the Mycotic Ulcer Treatment Trial (MUTT) II became available

45 he Steroids for Corneal Ulcers Trial (SCUT), Mycotic Ulcer Treatment Trial (MUTT), and Byers Eye Inst

46 hieved microbiological cure at 6 days in the Mycotic Ulcer Treatment Trial I (MUTT-I).

47 The Mycotic Ulcer Treatment Trial I was a randomized, double

48 The Mycotic Ulcer Treatment Trial I was a randomized, double

49 Design, Setting, and Participants: The Mycotic Ulcer Treatment Trial II (MUTT II), a multicente

50 This is a secondary analysis of Mycotic Ulcer Treatment Trial II, a multicenter, double-

51 participated in 1 of 3 clinical trials: the Mycotic Ulcer Treatment Trials (MUTT) I or II or the Cro